Latest Regulatory News

North Stawell Minerals has announced a combined $3.6 million capital raise through a placement and a pro-rata entitlement offer, aiming to bolster its exploration activities without materially altering company control.

Johns Lyng Group has received a conditional, non-binding acquisition proposal from Pacific Equity Partners, sparking a potential shift in ownership with key management poised to retain stakes. The company has granted exclusivity for due diligence, setting the stage for a possible binding offer.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Olympio Metals has secured approvals to drill up to 38 holes totaling 10,000 meters at its Bousquet Gold Project in Quebec, aiming to unlock high-grade gold potential along the prolific Cadillac Break. Drilling is set to start imminently, targeting promising zones with historic intercepts.

BluGlass Limited has extended the closing date of its Share Purchase Plan to June 13, 2025, giving eligible shareholders more time to subscribe at a discounted price. The move aims to maximize participation ahead of a crucial shareholder vote.

Helia Group announces the departure of CEO Pauline Blight-Johnston after five years, appointing CFO Michael Cant as interim CEO amid evolving market conditions. The leadership change signals a strategic pivot for the lender mortgage insurer.

IperionX has secured its first U.S. Army task order worth $1.3 million under a $99 million SBIR Phase III contract, marking a significant step in reshoring titanium production for U.S. defense needs.

OD6 Metals has secured a second regulatory approval to extend its Phase 2 drilling at the historic Gulf Creek Copper Project, targeting promising repeat mineral structures and deepening exploration near recent high-grade intercepts.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

European Lithium Ltd has released assay results from deep diamond drilling at Greenland’s Tanbreez Project, revealing high-grade rare earth mineralisation below the current resource estimate and setting the stage for resource expansion.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

IDM International shareholders have overwhelmingly approved Blackstone Minerals’ acquisition via a scheme of arrangement, setting the stage for a transformative merger in the copper-gold mining sector.